XETR
NN6
Market cap20mUSD
Apr 11, Last price
1.41EUR
1D
0.00%
1Q
1.44%
Jan 2017
53.08%
IPO
-22.95%
Name
NanoRepro AG
Chart & Performance
P/E
—
P/S
5.60
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.43%
Rev. gr., 5y
3.39%
Revenues
3m
-91.56%
Net income
0k
P
CFO
-10m
L
Dividend
Jun 16, 20230.15 EUR/sh
Profile
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 3,247 -91.56% | 38,488 -76.35% | |||||||
Cost of revenue | 5,851 | 28,587 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,604) | 9,901 | |||||||
NOPBT Margin | 25.73% | ||||||||
Operating Taxes | (640) | ||||||||
Tax Rate | |||||||||
NOPAT | (2,604) | 10,542 | |||||||
Net income | (3,724) -112.53% | ||||||||
Dividends | (1,934) | (6,452) | |||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (438) | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 1 | ||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 409 | 860 | |||||||
Net debt | (19,305) | (31,285) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (10,264) | 13,150 | |||||||
CAPEX | (3,306) | ||||||||
Cash from investing activities | (2,028) | (3,306) | |||||||
Cash from financing activities | (2,372) | (6,602) | |||||||
FCF | (2,922) | 36,992 | |||||||
| Balance | |||||||||
Cash | 20,621 | 31,260 | |||||||
Long term investments | (1,316) | 25 | |||||||
Excess cash | 19,143 | 29,361 | |||||||
Stockholders' equity | 18,120 | 47,433 | |||||||
Invested Capital | 22,664 | 18,881 | |||||||
ROIC | 36.68% | ||||||||
ROCE | 20.49% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 12,713 | 12,904 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (2,583) | 9,901 | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||